(DJ Bolsa)--AstraZeneca said the U.S. Food and Drug Administration approved the use of its Imfinzi immunotherapy along with chemotherapy for endometrial cancer.

The British-Swedish pharma giant said Monday that it received approval in the U.S. for the drug--in combination with carboplatin and paclitaxel followed by Imfinzi monotherapy--to be used to treat adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair ...